	1077286
To: 5.1.2e 1.2 5.1.2e 6.1.2e 6.1.2e 6.1.2e @rivm.nl] From: 5.1.2e 5.1.2e 5.1.2e 6.1.2e 5.1.2e @rivm.nl] Sent: Tue 1/26/2021 1:52:17 PM Subject: RE: ProMED Digest, Vol 103, Issue 64 Received: Tue 1/26/2021 1:52:18 PM	
Hi,	
Dank voor het doorsturen 5.1.2e Symptomatisch opvallend, het report benadrukt dit ook wel, dat de overleden Zweedse tijger ook severe neurological symptoms vooralsnog zonder duidelijk substraat bij autopsie. Van humane autopsiestudies weten we er in sommige casus ook sprake kan zijn van CZS-betrokkenheid: https://www.nature.com/articles/s41582-020-00453-w Dat zou voor deze tijger toch ook in die richting kunnen wijzen. @ 5.1.2e weet jij of eerdere pathologie bij geïnfecteerde dieren, afgezien van proefdierstudies, vooral respiratoir was?	had,
Groet, 5.1.2e	
Original Message From: 5.1.2e @promedmail.org < 5.1.2e @promedmail.org> On Behalf Of 5.1.2e @promedmail.org Sent: dinsdag 26 januari 2021 13:00 To: 5.1.2e @promedmail.org Subject: ProMED Digest, Vol 103, Issue 64	1
Today's Topics:	
 PRO/AH/EDR> COVID-19 update (33): Sweden, zoo, tiger, lion (<u>5.1.2e</u> @promedmail.org) PRO/EDR> Influenza (03): WHO global update, Europe (Ukraine) (<u>5.1.2e</u> @promedmail.org) 	
Message: 1 Date: Mon, 25 Jan 2021 15:00:34 +0000 From: 5.1.2e @promedmail.org Subject: PRO/AH/EDR> COVID-19 update (33): Sweden, zoo, tiger, lion To: 5.1.2e @promedmail.org, 5.1.2e @promedmail.org, 5.1.2e @promedmail.org Message-ID: 5.1.2e @email.amazonses.com>	
Content-Type: text/plain; charset=UTF-8	
CORONAVIRUS DISEASE 2019 UPDATE (33): SWEDEN, ZOO, TIGER, LION ************************************	
Date: Sun 24 Jan 2021 From: < 5.1.2e @sva.se> [edited]	
Please find below information on SARS-CoV-2 confirmed in a tiger and 2 lions at a Zoo in Sweden.	
On [13 Jan 2021], The National Veterinary Institute (SVA) confirmed SARS-CoV-2 in a tiger held in a Zoo in Sweden. Samples from the same animal were simultaneously sent to IDEXX laboratories Germany, where SARS-CoV-2 also was confirmed [14 Jan 2021].	5,
Whole-genome sequencing at the SVA showed that the virus belongs to the global lineage B1.177.21.	

Necropsy was performed at the SVA on [16 Jan 2021]. Macroscopical lesions of the respiratory tract were mild and unspecific. Convincing signs of pneumonia were not seen. Some blood-tinged mucus was present in the lower part of the trachea and bronchi. Findings in other organs were preliminary considered to be age related and thus probably not related to SARS-CoV-2. Results from histological examinations are pending.

The tiger was a 17-year-old female, which was euthanised [11 Jan 2021] for animal welfare reasons due to severe respiratory and neurological symptoms, high age, and low possibilities for recovery. The symptoms started with loss of appetite [9 Jan 2021], but rapidly worsened [11 Jan 2021] in the morning and the animal was euthanised and sampled the same morning. A male tiger kept in the same enclosure as the female has shown moderate respiratory symptoms, but no neurological symptoms.

A group of lions, consisting of 2 adults and 2 subadults, kept in the same house, have also shown mild respiratory symptoms but no neurological symptoms and are otherwise clinically unaffected with normal appetite. Fecal samples from the lions, received at a later date, were also confirmed positive for SARS-CoV-2.

Staff taking care of these groups of animals also had symptoms: one of the sick persons tested positive for SARS-CoV-2/Covid-19, while 3 more are awaiting their results.

The Zoo is closed for the season, and further internal biosafety measures have been taken by the responsible veterinarian on site.

Department of Disease Control and Epidemiology Acting State Epizootiologist Swedish National Veterinary Institute (SVA)

[Infection by SARS-CoV-2 has been confirmed so far in carnivores (Order Carnivora) of 3 families, canids (dogs and raccoon dogs), felids (cats, tigers, lions, puma/cougar, and snow leopard), and mustelids (ferrets and minks). Lions and tigers experienced respiratory disease due to COVID-19 in USA at the Bronx Zoo (New York) in April 2020 and tigers with mild respiratory sings tested positive at Zoo Knoxville (Tennessee) in October 2020. Lions were infected at the Barcelona Zoo (Spain) in December 2020. All infections detected in carnivores were from animals held captive, except for the recent record of a wild mink captured and sampled in Utah (USA). The susceptibility of carnivores warrants surveillance and research in wild populations, as introduction and possible establishment of SARS-CoV-2 in those populations might result in conservation problems and/or compartments in which the virus might evolve and remain with potential for future human exposures. - Mod.PMB

HealthMap/ProMED map: Sweden: <http://healthmap.org/promed/p/108>] [See Also: COVID-19 update (13); animal, USA, zoo, gorilla http://promedmail.org/post/20210112.8095510 2020 COVID-19 update (538): USA, animal, zoo, snow leopard http://promedmail.org/post/20201214.8017000 COVID-19 update (525): Spain, animal, zoo, lion, human http://promedmail.org/post/20201208.8002466 COVID-19 update (469): USA (TN) zoo, tiger http://promedmail.org/post/20201104.7915683 COVID-19 update (356): South Africa (GT) animal, puma, zoo, OIE http://promedmail.org/post/20200813.7673666 COVID-19 update (143): USA (NY) animal, zoo, tiger, lion, tests http://promedmail.org/post/20200430.7284183 COVID-19 update (141): India, animal, wild tiger, susp, clarification, RFI http://promedmail.org/post/20200430.7281768 COVID-19 update (138): India, animal, wild tiger, fatal http://promedmail.org/post/20200428.7275765 COVID-19 update (135): Netherlands (NB) animal, farmed mink http://promedmail.org/post/20200427.7272289 COVID-19 update (130): USA (NY) zoo, tiger, lion, new cases http://promedmail.org/post/20200425.7266556 COVID-19 update (85): USA (NY) tiger, OIE http://promedmail.org/post/20200406.7191480 COVID-19 update (84): USA, tigers http://promedmail.org/post/20200406.7191352 COVID-19 update (76): China (HU) animal, cat, owned, stray, seropositive http://promedmail.org/post/20200403.7179946 COVID-19 update (75): China (Hong Kong) cat, OIE http://promedmail.org/post/20200403.7179945 COVID-19 update (70): China (Hong Kong) cat, pets & stock http://promedmail.org/post/20200402.7173286 COVID-19 update (58): Belgium, cat, clinical case, RFI http://promedmail.org/post/20200327.7151215

1077286

COVID-19 update (57): global, re-using PPE, DR Congo, more countries, WHO http://promedmail.org/post/20200327.7149046 COVID-19 update (56): China (Hong Kong) animal, dog, final serology positive http://promedmail.org/post/20200326.7146438 COVID-19 update (45): China (Hong Kong) animal, dog, 2nd case PCR positive http://promedmail.org/post/20200319.7112693 COVID-19 update (37): China (Hong Kong) animal, dog, prelim, serology negative http://promedmail.org/post/20200312.7081842 COVID-19 update (30): China (Hong Kong) dog, susp, serology pending http://promedmail.org/post/20200306.7057595 COVID-19 update (25): China (Hong Kong) dog, susp, OIE http://promedmail.org/post/20200302.7040373 COVID-19 update (22): companion animals, dog susp, RFI http://promedmail.org/post/20200229.7036661 COVID-19 update (17): China, animal reservoir, wildlife trade & consumption http://promedmail.org/post/20200225.7024245 COVID-19 update (11): animal reservoir, intermediate hosts, pangolin susp http://promedmail.org/post/20200220.7009213 COVID-19 update (08): companion animals, RFI http://promedmail.org/post/20200218.7002276 COVID-19 update (06): animal reservoir, intermediate hosts http://promedmail.org/post/20200217.6997782 Novel coronavirus (42): China, global, COVID-19, SARS-CoV-2, WHO http://promedmail.org/post/20200211.6979942 Novel coronavirus (40): animal reservoir, pangolin poss intermediate host, RFI http://promedmail.org/post/20200210.6972104 Novel coronavirus (28): China (HU) animal reservoir http://promedmail.org/post/20200201.6943858 Novel coronavirus (22): reservoir suggested, bats http://promedmail.org/post/20200129.6930718 Novel coronavirus (20): China, wildlife trade ban http://promedmail.org/post/20200127.6922060 Novel coronavirus (18): China (HU) animal reservoir http://promedmail.org/post/20200125.6915411 Novel coronavirus (15): China (HU) wild animal sources http://promedmail.org/post/20200123.6909913 Novel coronavirus (03): China (HU) animal reservoir suggested, RFI http://promedmail.org/post/20200114.6887480 Novel coronavirus (01): China (HU) WHO, phylogenetic tree http://promedmail.org/post/20200112.6885385 Undiagnosed pneumonia - China (HU) (07): official confirmation of novel coronavirus http://promedmail.org/post/20200108.6878869]pmb/mj/lxl

Message: 2 Date: Mon, 25 Jan 2021 15:14:00 +0000 From: 51.2e @promedmail.org Subject: PRO/EDR> Influenza (03): WHO global update, Europe (Ukraine) To: 5.1.2e @promedmail.org, 5.1.2e @promedmail.org Message-ID:

@email.amazonses.com>

Content-Type: text/plain; charset=UTF-8

INFLUENZA (03): WHO GLOBAL UPDATE, EUROPE (UKRAINE)

A ProMED-mail post <http://www.promedmail.org> ProMED-mail is a program of the International Society for Infectious Diseases <http://www.isid.org>

In this update: [1] WHO global update [2] Europe (Ukraine)

[1] WHO global update Date: Mon 18 Jan 2021 Source: WHO, Surveillance and monitoring, influenza updates [edited] <https://www.who.int/influenza/surveillance_monitoring/updates/latest_update_GIP_surveillance/en/>

Influenza update -- 385 (based on data up to 3 Jan 2020)

Information in this report is categorized by influenza transmission zones, which are geographical groups of countries, areas, or territories with similar influenza transmission patterns

Summary

- The current influenza surveillance data should be interpreted with caution as the ongoing COVID-19 pandemic has influenced to varying extents health seeking behaviours, staffing/routines in sentinel sites, as well as testing priorities and capacities in Member States. The various hygiene and physical distancing measures implemented by Member States to reduce SARS-CoV-2 virus transmission have likely played a role in reducing influenza virus transmission.

- Globally, despite continued or even increased testing for influenza in some countries, influenza activity remained at lower levels than expected for this time of the year.

- In the temperate zone of the northern hemisphere, influenza activity remained below inter-seasonal levels, though sporadic detections of influenza A and B viruses were reported in some countries.

- In the temperate zone of the southern hemisphere, influenza activity was reported at inter-seasonal level.

- In the Caribbean and Central American countries, increased influenza detections were reported in Haiti in recent weeks. Severe acute respiratory infection (SARI) activity, decreased in most reporting countries.

- In tropical South America, there were no influenza detections in this reporting period.

- In tropical Africa, influenza activity continued to be reported in Western Africa.
- In Southern Asia, sporadic influenza detections were reported across reporting countries.
- In South East Asia, there were no influenza detections reported in this reporting period.

- Worldwide, influenza B detections accounted for the majority of the very low numbers of detections reported.

National Influenza Centres (NICs) and other national influenza laboratories from 82 countries, areas, or territories reported data to FluNet for the time period from [21 Dec 2020] to [3 Jan 2021] (data as of 15 Jan 2021 4:26:22 UTC). The WHO GISRS [Global Influenza Surveillance and Response System] laboratories tested more than 200

863 specimens during that time period. A total of 409 specimens were positive for influenza viruses, of which 121 (29.6 percent) were typed as influenza A and 288 (70.4 percent) as influenza B. Of the sub-typed influenza A viruses, 19 (54.3 percent) were influenza A (H1N1)pdm09 and

16 (45.7 percent) were influenza A(H3N2). All the characterized B viruses (129) belonged to the B-Victoria lineage.

During the COVID-19 pandemic, WHO encourages countries to continue routine influenza surveillance, test samples from influenza surveillance sites for influenza and SARS-CoV-2 viruses where resources are available, and report epidemiological and laboratory information in a timely manner to established regional and global platforms. Updated considerations for addressing disruptions in the influenza sentinel surveillance and extending to include COVID-19 wherever possible are available in the interim guidance, Maintaining surveillance of influenza and monitoring SARS-CoV-2 -- adapting Global Influenza Surveillance and Response System (GISRS) and sentinel systems during the COVID-19 pandemic [].

Updated algorithms for testing of both influenza and SARS-CoV-2 for surveillance are also included.

Communicated by: ProMED from HealthMap Alerts < 5.1.2e @promedmail.org>

[2] Ukraine

Date: Sun 16 Jan 2021 12:53:31 AM Source: MENAFN, UkrinForm (National News Agency of Ukraine) report [edited] https://menafn.com/1101440569/Almost-90000-ARVI-flucases-recorded-in-Ukraine-over-last-week&source=30

Almost 90 000 cases of influenza and acute respiratory viral infection (ARVI) have been recorded in Ukraine over the past week, according to data provided by the Health Ministry.

"Over the past week, 89 133 people fell ill with ARVI, 35.5 percent of whom were children under the age of 17. The incidence rate is 234.6 per 100 000 population, which is 51.4 percent less than the epidemic threshold calculated for Ukraine," the report reads.

The Health Ministry notes that no lethal cases related to influenza have been reported.

Communicated by: ProMED from HealthMap Alerts < 5.1.2e @promedmail.org>

[HealthMap/ProMED map of Ukraine: <http://healthmap.org/promed/p/123>

Despite the great challenges it poses, the COVID-19 pandemic provides an opportunity to strengthen core surveillance capacities that can deliver public health benefits during and well beyond this emergency.

1077286 It is important to understand that the key measures recommended for the prevention of influenza include cough etiquette, hand washing, and annual vaccination, particularly in the high-risk groups. The 1st 2 are the same non-pharmaceutical measures (NPIs) as those recommended for COVID-19 protection, and efficacious vaccines are now available for COVID-19 as well as for influenza.

It is clear both influenza and COVID-19 can be prevented by mask-wearing, frequent and thorough hand washing, coughing into the crook of your elbow, staying home when sick, and limiting contact with people who are infected. Another strategy to reduce the likelihood of a double epidemic would be to strengthen existing influenza vaccination programs.

In addition to continuing adherence to non-pharmaceutical interventions (NPIs), one way to prepare for a possible double epidemic is to ramp up the testing capacity for both COVID-19 and seasonal infections. Combination testing for both COVID-19 and influenza could also be beneficial, as a single sample could be used to distinguish the 2 infections in patients presenting with similar symptoms. Another reason it is important to determine whether respiratory symptoms are due to influenza or to COVID-19 (or both) is that mitigation efforts for the former aren't as strict as for the latter. - Mod.UBA]

[See Also: 2020

Influenza (14): South Korea, vaccine http://promedmail.org/post/20201113.7935700 Influenza (12): WHO global update, Europe (Ukraine), USA http://promedmail.org/post/20201104.7895442 Influenza (11): South Korea, Taiwan http://promedmail.org/post/20201028.7898480 Influenza (10): South Korea http://promedmail.org/post/20201025.7888308 Influenza (09): WHO global update http://promedmail.org/post/20201018.7860441 Influenza (05): WHO global update http://promedmail.org/post/20200606.7410880 Influenza (04): WHO global update, Americas, Asia http://promedmail.org/post/20200223.7016972 Influenza (03): WHO global update, Asia, Americas, Europe http://promedmail.org/post/20200209.6951059 Influenza (02): WHO global update, Asia, Americas http://promedmail.org/post/20200119.6881669 Influenza (01): Asia, Americas, Europe, research http://promedmail.org/post/20200108.6871893 2019

Influenza (32): WHO global update http://promedmail.org/post/20191229.6855678 Influenza (31): WHO global update, Asia, Americas, Caribbean http://promedmail.org/post/20191213.6806605 Influenza (30): WHO global update, Americas, Caribbean, drugs http://promedmail.org/post/20191127.6798010 Influenza (29): WHO global update, Asia, America, Europe http://promedmail.org/post/20191102.67488220 Influenza (28): Asia, PAHO update, USA, treatment http://promedmail.org/post/20191020.6731512 Influenza (27): WHO global update, vaccine http://promedmail.org/post/20191016.672726604 Influenza (26): WHO global update, vaccine http://promedmail.org/post/20191004.6702930 Influenza (25): WHO global update, Australia http://promedmail.org/post/20190908.6656310 Influenza (24): WHO global update, Asia, Australia http://promedmail.org/post/20190829.6631162 Influenza (21): WHO global update http://promedmail.org/post/20190726.6582424 Influenza (20): Asia, Africa, Australia, vaccine, WHO http://promedmail.org/post/20190719.6554487 Influenza (19): Australia, Asia, Americas http://promedmail.org/post/20190702.6547597 Influenza (18): WHO global update, Americas, Asia http://promedmail.org/post/20190622.6522954 Influenza (17): WHO global update, Asia, North America, Pacific, vaccine http://promedmail.org/post/20190609.6502103 Influenza (16): India, Australia, seasonal activity http://promedmail.org/post/20190526.6482726 Influenza (15); WHO global update. Australia, seasonal activity

http://promedmail.org/post/20190520.6468392 Influenza (14): Australia, seasonal activity http://promedmail.org/post/20190512.6457546 Influenza (13): WHO global update, North America, Asia http://promedmail.org/post/20190502.6450034 Influenza (12): WHO global update, Asia http://promedmail.org/post/20190424.6432363 Influenza (11): Asia, Australia http://promedmail.org/post/20190413.6418287 Influenza (10): WHO global update http://promedmail.org/post/20190407.6401577 Influenza (09): WHO global update, N. America, antiviral resistance http://promedmail.org/post/20190331.6390424 Influenza (08); WHO global update, seasonal activity, Asia http://promedmail.org/post/20190307.6351658 Influenza (07): WHO global update, seasonal, Asia, Europe, vaccine http://promedmail.org/post/20190225.6326092 Influenza (06): Europe, Asia, N. America, Australia, Japan research http://promedmail.org/post/20190212.6302099 Influenza (05): vaccine effectiveness, comment http://promedmail.org/post/20190204.6293577 Influenza (04): seasonal activity, Europe, Asia, Africa, N. America, vaccine http://promedmail.org/post/20190203.6292286 Influenza (03): seasonal activity, multiple locations http://promedmail.org/post/20190129.6275544 Influenza (02): seasonal activity, multiple locations, antiviral resistance http://promedmail.org/post/20190122.6268175 Influenza (01): WHO global update, H3N2, oncology ward, 2017 http://promedmail.org/post/20190110.6247465 2018 Influenza (33): WHO global update, Georgia, India http://promedmail.org/post/20181228.6223446 Influenza (32): seasonal, USA, Italy http://promedmail.org/post/20181223.6219731 Influenza (31): Canada (AB) India (MH,TN) seasonal http://promedmail.org/post/20181204.6176611 Influenza (30): WHO global update http://promedmail.org/post/20181130.6169214 Influenza (25): WHO global update, ECDC, 2017-18 review http://promedmail.org/post/20180827.5979056 Influenza (20): USA (IN) swine origin H3N2v, new human case http://promedmail.org/post/20180701.5884141 Influenza (15): WHO global update, Brazil http://promedmail.org/post/20180517.5798872 Influenza (10): WHO global update, Kenya http://promedmail.org/post/20180310.5672765 Influenza (05): seasonal, multiple locations http://promedmail.org/post/20180121.5570116 Influenza (04): WHO global update, multiple locations, preparedness http://promedmail.org/post/20180113.5557168 Influenza (03): Asia (Pakistan, Nepal) http://promedmail.org/post/20180111.5551430 Influenza (02): increased seasonal activity, USA, Europe, Asia http://promedmail.org/post/20180104.5534440 Influenza (01): Pakistan (PB) H1N1 http://promedmail.org/post/20180101.5531217]sb/uba/mj/lxl

ProMED makes every effort to verify the reports that are posted, but the accuracy and completeness of the information, and of any statements or opinions based thereon, are not guaranteed. The reader assumes all risks in using information posted or archived by ProMED. ISID and its associated service providers shall not be held responsible for errors or omissions or held liable for any damages incurred as a result of use or reliance upon posted or archived material.

Donate to ProMED-mail. Details available at: ">https://isid.org/donate/>

Visit ProMED's web site at <https://www.promedmail.org>.

Send all items for posting to: 5.1.2e @promedmail.org. Please include your name and email in order for your contribution to be posted. You may subscribe/unsubscribe at <https://isid.org/promedmail-subscribe/>

End of ProMED Digest, Vol 103, Issue 64